Rates of PCR Negativity: LipoATRA Monotherapy Versus Oral ATRA Monotherapy
| Months From CR . | Current Study: Newly Diagnosed Patients PCR Negative/ Patients Evaluated* . | Oral ATRA: Relapsed Patients PCR Negative/ Patients Evaluated . | P Value (Fisher exact test) . |
|---|---|---|---|
| 3 | 12/12 | 0/7 | <.0001 |
| 6 | 8/9† | 0/5 | .003 |
| 9 | 5/6 | 0/1 | .286 |
| 12 | 4/4 | — | — |
| 15 | 3/3 | — | — |
| Months From CR . | Current Study: Newly Diagnosed Patients PCR Negative/ Patients Evaluated* . | Oral ATRA: Relapsed Patients PCR Negative/ Patients Evaluated . | P Value (Fisher exact test) . |
|---|---|---|---|
| 3 | 12/12 | 0/7 | <.0001 |
| 6 | 8/9† | 0/5 | .003 |
| 9 | 5/6 | 0/1 | .286 |
| 12 | 4/4 | — | — |
| 15 | 3/3 | — | — |
Table includes patients who received lipoATRA without idarubicin. If all patients are considered, the rates are 12/12 at 3 months, 8/9 at 6 months (with 1 additional patient positive then negative), 6/7 at 9 months, 6/7 at 12 months and 4/4 at 15 months.
If patient with positive then negative PCR result at 6 months is included, rate becomes 8/10 and P value = .007.